What is Cytrellis?
Cytrellis operates at the intersection of advanced engineering and dermatology, focusing on the development of a novel class of aesthetic devices. The company's core technology is engineered to address the physiological markers of aging, specifically sagging skin, by providing a non-invasive alternative to traditional surgical procedures. By eliminating the need for incisions, Cytrellis effectively mitigates the risk of scarring, positioning itself as a disruptive force in the multi-billion dollar aesthetic medical device market. Their strategic focus remains on clinical efficacy and patient-centric outcomes, ensuring that their medical hardware meets the rigorous demands of modern aesthetic practitioners.
How much funding has Cytrellis raised?
Cytrellis has raised a total of $86M across 4 funding rounds:
Series A
$7.1M
Series B
$28.5M
Debt
$350K
Series C
$50M
Series A (2015): $7.1M with participation from ARCH Venture Partners
Series B (2018): $28.5M led by Biomatics Capital, Partner Fund Management, Merz Venture Initiative, and ARCH Ventures
Debt (2020): $350K supported by PPP
Series C (2021): $50M featuring PFM Health Sciences, ARCH Venture Partners, Sands Capital, and D1 Capital Partners
Key Investors in Cytrellis
PFM Health Sciences
A prominent healthcare investment advisor managing approximately $2 billion in public and private assets, specializing in high-growth life sciences ventures.
ARCH Venture Partners
A premier early-stage venture capital firm that co-founds and scales life sciences companies by commercializing innovations from academic and national research institutions.
Biomatics Capital
A venture firm focused on the convergence of genomics and digital data, supporting transformative innovations that improve healthcare outcomes and reduce costs.
What's next for Cytrellis?
With the recent influx of capital, Cytrellis is poised to enter a critical phase of commercial expansion and product refinement. The company is expected to prioritize the scaling of its manufacturing capabilities and the broadening of its clinical distribution networks to meet rising global demand. Furthermore, the strategic nature of this latest financing suggests a focus on long-term market penetration and the potential for further R&D initiatives aimed at diversifying their portfolio of non-surgical interventions. As the firm transitions into this mature growth stage, the emphasis will likely shift toward optimizing operational efficiency and solidifying its leadership position within the aesthetic technology ecosystem.
See full Cytrellis company page
